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T
he prevalence of diabetes in the
world is growing at an unprece-
dented rate and rapidly becoming a
health concern and burden in both devel-
oped and developing countries (1). In ad-
dition, we are now witnessing an upsurge
in the incidence of type 2 diabetes in chil-
dren and adolescents, with the potential
of translating into a future catastrophic
disease burden as vascular complications
of the disease begin affecting a younger
population. Although there may be con-
tention regarding the impact of lowering
glycemia on macrovascular disease risk,
there is strong consensus of the deﬁnite
beneﬁts of lowering blood glucose to re-
ducetheriskofretinopathyandnephrop-
athy in either type 1 or type 2 diabetes
(2,3). Despite supporting data and multi-
ple guidelines advanced by professional
organizations, overall glycemic control
falls far below expectations (4). Overall,
36% of individuals with diabetes are at
recommended glycemic targets, with the
most difﬁcult-to-control cases repre-
sented by insulin-deﬁcient individuals on
insulin therapy to manage their diabetes
(4). Furthermore, as -cell dysfunction
progresses over time, many patients with
type 2 diabetes, treated with oral agents,
fail to achieve or maintain adequate gly-
cemic control. Unfortunately, in many of
these cases, antiglycemic therapy is not
adjusted or advanced, thereby exposing
patients to prolonged hyperglycemia and
the increased risk of diabetes-related
complications.Theterm“clinicalinertia,”
which has come to deﬁne the lack of ini-
tiation, or intensiﬁcation of therapy when
clinically indicated (5), is most pro-
nounced in the setting of insulin initia-
tion. Subjects with type 2 diabetes,
managed in a large integrated health care
system,wereinitiatedonadditionalblood
glucose–lowering treatment only when
the mean baseline A1C reached a value of
9.0% (6). Patients started on insulin had
an even higher mean A1C of 9.6% and
tendedtohavemoreseverebaselinecom-
plications and comorbidities than those
started on sulfonylurea, or metformin
therapy. In addition, the higher the start-
ing A1C when therapy was initiated or
changed, the less likely the patient was of
achieving adequate glycemic control (6).
Although specialists are slightly more
proﬁcientthangeneralpractitionersinin-
tensifying diabetes therapy when war-
ranted (7), overall clinical inertia results
in the majority of patients failing to
achieve, or maintain, adequate metabolic
goals from a period of months to several
years(8,9).Insummary,toimprovethese
suboptimal metabolic outcomes, and re-
duce the risk of disease-related complica-
tions, more intensive management of
glycemia is warranted, including the op-
tion of introducing insulin therapy earlier
than the current widely practiced sub-
standard of care.
INTRODUCTION OF INSULIN
EARLIER IN THE TREATMENT
PARADIGM— Typically, whereas
introducing insulin therapy in a more
timely fashion would signiﬁcantly im-
prove glycemic control among subjects
with type 2 diabetes, the question of in-
sulin initiation timing in relation to other
antiglycemic therapies is the subject of
considerable debate (10). While insulin
administration has the potential of
achieving the most effective reductions in
glycemic control, the initiation of insulin
therapy requires greater use of resources,
time,andeffortfromproviderandpatient
alike, compared with oral antidiabetic
therapies (11). Patient resistance to the
use of insulin therapy remains a chal-
lenge, especially in populations that may
have misgivings and misconceptions re-
garding the role of insulin replacement in
diabetes management.
Notwithstanding these issues, there
are speciﬁc populations that would
clearly beneﬁt from early, aggressive, and
targeted introduction of insulin therapy.
Forinstance,patientspresentingwithsig-
niﬁcant hyperglycemia may beneﬁt from
timely initiation of insulin therapy that
can effectively and rapidly correct their
metabolic imbalance and reverse the del-
eterious effects of excessive glucose (glu-
cotoxicity) and lipid (lipotoxicity)
exposure on -cell function and insulin
action (12). In vitro studies have demon-
strated that chronic hyperglycemia leads
to increased production of reactive oxy-
gen species, and subsequent oxidative
stress,whichappearstoaffectinsulinpro-
moter activity (PDX-1 and MafA binding)
andresultsindiminishedinsulingeneex-
pression in glucotoxic -cells (13). Inter-
estingly, in vitro experiments have shown
that these glucotoxic effects occur in a
continuum of glucose concentrations (no
clear threshold effect), are reversible with
reinstitution of euglycemic conditions,
and result in the greatest recovery of
-cellfunctionwithshorterperiodsofex-
posure to hyperglycemia (14). Various
studies have demonstrated improvement
in insulin sensitivity and -cell function
after correction of hyperglycemia with in-
tensive insulin therapy (15).
INTENSIVE INSULIN
TREATMENT AND -CELL
FUNCTION— A number of trials
haveevaluatedthestrategyofimplement-
ing short-term aggressive insulin replace-
ment as ﬁrst-line therapy in the
management of hyperglycemia in newly
diagnosed type 2 diabetes (Table 1), with
the goal of improving and preserving
-cell function, reducing insulin resis-
tance, and maintaining optimal glycemic
control through disease “remission” (16–
18). In these studies, intensive insulin
therapy was delivered via multiple daily
insulin injections, or insulin pump ther-
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fusion), over a period of 2–3 weeks, with
achievement of euglycemia in 90% of
subjects on completion of insulin treat-
ment. After insulin withdrawal, patients
were maintained on diet therapy only,
with 42–69% maintaining euglycemia 12
or more months after treatment. Patients
who achieved and maintained long-term
euglycemia tended to have a better re-
sponse to insulin therapy, as well as asso-
ciated improvements in -cell function,
including ﬁrst-phase insulin release, as
measured by homeostasis model assess-
ment of -cell function (HOMA-B) and
intravenous glucose tolerance tests.
Improvements in -cell function and
insulin action have also been reported
when euglycemia is achieved with nonin-
sulin therapies (19). Unfortunately, as il-
lustratedbytheU.K.ProspectiveDiabetes
Study,long-termglycemiccontrolintype
2 diabetes is difﬁcult to maintain, regard-
less of the therapeutic intervention due,
in part, to progressive loss of -cell func-
tion over time. The recently published A
Diabetes Outcome Progression Trial
(ADOPT) demonstrated longer mainte-
nance of glycemic control in patients us-
ing a thiazolidinedione (rosiglitazone)
compared with glyburide or metformin
monotherapy, although -cell function,
asmeasuredbyHOMA-Bwasnodifferent
at the end of the trial between the rosigli-
tazone and sulfonylurea groups (20); the
beneﬁtsindurabilityofcontrolseemedto
have been a result of improved insulin
sensitivity.
A recent study comparing intensive
insulin therapy (multiple daily insulin in-
jections or continuous subcutaneous in-
sulin infusion) with oral hypoglycemic
agents (glicazide and/or metformin) in
newly diagnosed patients with type 2 di-
abetes provided some provocative results
(21). In this trial, 92% of 382 subjects
with poorly controlled diabetes achieved
glycemic targets (fasting and 2-h post-
prandial capillary glucose levels of 110
mg/dl and 144 mg/dl, respectively)
within an average of 8 days from start of
therapy (Table 2). Treatment was with-
drawn after 2 weeks of normoglycemia,
followed by diet and exercise manage-
ment. A greater proportion of patients
randomized to intensive insulin therapy
achieved glycemic targets and did so in a
shorter period compared with oral agent
therapy (Table 2). Shortly after discon-
tinuing antiglycemic treatment, measures
of ﬁrst-phase insulin release, HOMA-B
and HOMA-IR were similar among all
treatment groups. By the end of 1 year,
remission rates were signiﬁcantly higher
in the groups that had received initial in-
sulin therapy (51 and 45% in the contin-
uous subcutaneous insulin infusion and
multiple daily insulin injections groups,
respectively), compared with 27% in the
oral therapy group. Whereas in the oral
agent group, acute insulin response at 1
yeardeclinedsigniﬁcantlycomparedwith
immediate post-treatment, it was main-
tained in the insulin treatment groups. Of
note, responders typically had higher
BMI, less baseline hyperglycemia, and
greater responsiveness to therapy than
nonresponders.
Another study comparing early and
continued insulin treatment versus oral
agent therapy (glibenclamide) over a pe-
riod of 2 years in recently diagnosed pa-
tients with type 2 diabetes showed better
long-term glycemic control and -cell
function in the insulin-treated group
(22). There was no difference in weight
gain between insulin and oral agent ther-
apyandnoreportedcasesofseverehypo-
glycemia, reﬂecting easier-to-manage
glycemia, probably as a result of better
endogenous insulin production.
POTENTIAL
PHYSIOLOGICAL EFFECTS
OF INSULIN REPLACEMENT
THERAPY— What could account for
some of the differences in -cell function
seen in studies with early aggressive insu-
Table 1—Baseline characteristics and outcomes of patients with type 2 diabetes receiving temporary insulin therapy at disease diagnosis
n Age BMI
Baseline
A1C
(%)
Insulin dose
(units   kg
1  
day
1)
Days to
glycemic
control
Duration
insulin
therapy
(weeks)
% Early
responders
% Sustained
responders Weight change
Ilkova et al. (17) 13 50 27 11.2 0.61 1.9 2 92 69 (26 months) 0.4 kg
Li et al. (16) 126 50 25 10.0 0.7 6.3 2 90 42 (24 months) 0.04 kg/m
2
Ryan et al. (18) 16 52 31 11.8 0.37–0.73 14 2–3 88 44 (12 months) 0.5 kg/m
2
Early responders are subjects who achieved euglycemia with insulin treatment, and late responders are subjects who maintained long-term euglycemia without
pharmacotherapy after the initial insulin treatment.
Table 2—Baseline characteristics and clinical outcomes comparing subjects treated with in-
sulin or oral agent therapies lasting for 2 weeks after achievement of normoglycemia
Continuous
subcutaneous insulin
infusion
Multiple
daily
injections Oral agents
n 133 118 101
Age (yrs) 50 51 52
BMI (kg/m
2) 25 24 25
Baseline A1C (%) 9.8 9.7 9.5
% Achieving euglycemia 97 95 83
Time to euglycemia (days) 4 5.6 9.3
Daily drug doses 0.68 units/kg (mean) 0.74 units/kg
(mean)
Glicazide 160 mg 
metformin 1,500 mg
(max median)
 in AIR*
(pmol   l
1   min
1) 951 800 831
AIR (median) in remission
groups at 1 year 809 729 335†
FromWengetal.(21).*ChangeinmedianAIR(acuteinsulinresponse)betweenbaselineandtreatmentend.
†P  0.05 compared with continuous subcutaneous insulin infusion.
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inﬂammatory effects of an insulin
infusion on obese subjects without diabe-
tes demonstrated suppression of nuclear
factor B. Nuclear factor B is the key
transcription factor responsible for the
transcription of proinﬂammatory cyto-
kines, adhesion molecules and enzymes
responsible for producing reactive oxy-
gen species (23). As a consequence, insu-
lin infusion signiﬁcantly suppressed
generation of reactive oxygen species and
decreased concentrations of plasma solu-
ble intercellular adhesion molecule-1 (sI-
CAM-1), monocyte chemo-attractant
protein-1 (MCP-1), and plasminogen ac-
tivator inhibitor-1 (PAI-1), among other
observed anti-inﬂammatory actions (24).
Could the timing of the intervention
affect the metabolic response to insulin
therapy? For example, loss of ﬁrst-phase
insulin response, possibly as a conse-
quence of glucotoxicity, is evident with
fasting plasma glucose concentrations
115mg/dl(25).Often,whendiabetesis
diagnosed, fasting plasma glucose levels
are usually signiﬁcantly higher, and may
have been so for quite some time (26),
exposing -cells to chronic hyperglyce-
mia and consequent -cell decompensa-
tion (13). It could be hypothesized that
early aggressive physiologic insulin re-
placement with both prandial and basal
coverage results in rapid improvement in
glucolipotoxicity, reduction of the in-
ﬂammatory milieu, and consequent
greater preservation of -cell function.
Some of these improvements in -cell
function were also evident after rigor-
ous management with glyburide and
metformin.
INSULIN REPLACEMENT
OPTIONS AND STRATEGIES—
Whereas the use of insulin therapy in
newly diagnosed subjects with type 2 di-
abetes appears to be associated with a low
riskofhypoglycemiaandweightgain,the
use of algorithm-driven insulin replace-
ment in more advanced disease is often
associated with a greater incidence of
weight gain and hypoglycemia. Individu-
alizing the insulin prescription may min-
imize some of these adverse outcomes.
UsingtheA1Cstatusofapatient,thefast-
ing blood glucose, and if available, the
postprandial glucose could assist the pro-
vider in individualizing insulin replace-
ment. Published trials in suboptimally
controlled insulin-naive type 2 diabetes
seem to indicate that basal insulin re-
placement yields similar effectiveness,
but with less weight gain, and hypoglyce-
mia risk than basal/prandial or mixed in-
sulin strategies, when baseline A1C is
8.5% (27). Thus, in a patient whose
predominant glycemic burden occurs
overnight and whose A1C level is within
1–2% points of target, starting with a low
dose of basal insulin (0.2 units   kg
1  
day
1) and adjusting the dose to achieve
fasting blood glucose levels 110–130
mg/dl often proves an effective strategy.
With higher A1C levels, replacing pran-
dial insulin, with or without basal insulin
coverage,resultsingreaterA1Creduction
than basal-only replacement, albeit at the
expense of more weight gain and hypo-
glycemia (28). For example, patients in-
adequately controlled on basal insulin
can be started on one or more doses of
rapid-acting insulin (0.05 units/kg/meal)
before one or more meals (usually the
largest meals), and the insulin dose ti-
trated to achieve postprandial blood glu-
cose levels 180 mg/dl. A basal/bolus
insulin replacement, giving patients ﬂex-
ible prandial dosing instructions, as op-
posed to ﬁxed doses of premeal insulin,
has been shown to be associated with
equivalent glycemic control, but with less
weight gain (29). Furthermore, the use of
basalinsulinanalogs(glargineordetemir)
is associated with less hypoglycemia (es-
pecially nocturnal hypoglycemia) and, in
the case of insulin detemir, less weight
gain than human NPH insulin (27,30).
CONCLUSIONS— In summary, ag-
gressive and often temporary use of insu-
lin therapy at disease onset in type 2
diabetes is associated with effective glyce-
miccontrolwithminimalweightgainand
hypoglycemia. Early restitution of physi-
ologicinsulinsecretionandglycemiccon-
trol could be, in theory, followed by
therapies to prolong maintenance of eug-
lycemia, such as thiazolidinediones- (20)
or glucagons-like peptide 1–based inter-
ventions (to date not clinically tested). A
more timely and selective introduction of
insulin replacement therapy, as -cell
function progresses, could facilitate the
achievementandmaintenanceofeuglyce-
mia and thus reduce disease-associated
complications.
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